Pulmozyme and Tracleer drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pulmozyme (dornase alfa) and Tracleer (bosentan). Common drug interactions include disease progression among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Pulmozyme and Tracleer. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Pulmozyme?

Pulmozyme has active ingredients of dornase alfa. It is often used in cystic fibrosis. eHealthMe is studying from 20,012 Pulmozyme users. Check the latest studies of Pulmozyme.

What is Tracleer?

Tracleer has active ingredients of bosentan. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,125 Tracleer users. Check the latest studies of Tracleer.

On Jul, 09, 2026

17 people who take Pulmozyme and Tracleer together, and have interactions are studied.

Pulmozyme and Tracleer drug interactions.

What are the common drug interactions of Pulmozyme and Tracleer, by gender? *:

female:

Disease progression
Enterococcal sepsis
Fungaemia (fungi circulate in the blood)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Nasopharyngitis (inflammation of the nasopharynx)
Right ventricular failure (right half of the heart fails to work)
Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)
Fatigue (feeling of tiredness)
Dyspnoea (difficult or laboured respiration)
Blood urea increased

male:

Dyspnoea (difficult or laboured respiration)
Nausea (feeling of having an urge to vomit)
Aspartate aminotransferase increased
Blood sodium decreased
Cardiac failure
Cardiomegaly (increased size of heart than normal)
Generalised oedema (swelling all over the body)
Hypokalaemia (low potassium)
Pericardial effusion (fluid around the heart)
Pleural effusion (water on the lungs)

What are the common drug interactions of Pulmozyme and Tracleer, by age (0-1 to 60+)? *:

0-1:

Bronchial secretion retention
Electrolyte imbalance
Gastroenteritis norovirus (inflammation of stomach and intestine caused by norovirus infection)
Respiratory distress (difficulty in breathing)
Tracheostomy malfunction (a surgical opening of trachea not working normally)
Hospitalisation

2-9:

Adverse drug reaction
Bacterial infection
Blood urea increased
Catheter site discharge
Catheter site erythema (redness of skin at catheter site)
Catheter site pain
Diarrhoea
Fatigue (feeling of tiredness)
Haemoglobin increased
Heart rate decreased

10-19:

Ascites (accumulation of fluid in the abdominal cavity)
Aspartate aminotransferase increased
Cardiomegaly (increased size of heart than normal)
Generalised oedema (swelling all over the body)
Hypokalaemia (low potassium)
Pericardial effusion (fluid around the heart)
Weight increased
Dyspnoea (difficult or laboured respiration)
Pleural effusion (water on the lungs)
Pyrexia (fever)

20-29:

Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Fluid retention (an abnormal accumulation of fluid in the blood)
General physical health deterioration (weak health status)
Oxygen saturation decreased
Pulmonary function test decreased
Concomitant disease progression (progress in accompanying disease)
Disease progression
Right ventricular failure (right half of the heart fails to work)
Cardiac failure

30-39:

Atrial tachycardia (rhythm disturbance that arises in the atria)
Blood magnesium decreased
Catheter related complication
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dyspnoea (difficult or laboured respiration)
Enterococcal sepsis
Fungaemia (fungi circulate in the blood)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 29.41%
Pulmonary Hypertension Secondary (increase in blood pressure in the lung artery): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Pulmozyme and Tracleer?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously